Every material Form 8-K Cytokinetics filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cytokinetics reported third quarter 2026 results, with total revenue of $47.6 million, up from $1.9 million a year earlier, driven by $44.5 million in MYQORZO net product revenue. The net loss narrowed to $190.1 million, or $1.37 per share, from $306.2 million, or $2.55 per share, a year earlier, and the company reaffirmed its full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million.
Total Q3 2026 revenue was $47.6 million, including $44.5 million of MYQORZO net product revenue and $3.1 million of collaboration revenue.
Net loss for Q3 2026 was $190.1 million, or $(1.37) per share, versus $306.2 million, or $(2.55) per share, in Q3 2025.
Cash, cash equivalents and investments were approximately $1.6 billion at September 30, 2026, compared with $1.7 billion at June 30, 2026.
Full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million was reaffirmed.
Cytokinetics reported second quarter 2026 total revenue of $28.6 million, down from $66.8 million a year earlier, when the company recorded $64.4 million in license and milestone revenue. The net loss widened to $198.8 million, or $(1.50) per share, from $134.4 million, or $(1.12) per share. The company also raised its full year 2026 GAAP combined R&D and SG&A expense guidance, which it attributed to commercial readiness investments ahead of a potential 2027 nHCM launch of MYQORZO.
Total revenue was $28.6 million in Q2 2026 versus $66.8 million in Q2 2025; Q2 2026 had no license and milestone revenue.
MYQORZO net product revenue was $25.3 million, including $23.0 million from the U.S. and $2.3 million from Europe.
Net loss was $198.8 million, or $(1.50) per share, compared with $134.4 million, or $(1.12) per share, a year earlier.
2026 GAAP combined R&D and SG&A expense guidance rose to $860 million to $890 million from $830 million to $870 million.
Cytokinetics reported first quarter 2026 results, with total revenues of $19.4 million versus $1.6 million a year earlier, including $4.8 million of MYQORZO net product revenue from its initial partial quarter of U.S. sales. The net loss widened to $206.0 million, or $(1.67) per share, from $161.4 million, or $(1.36) per share, as selling, general and administrative expenses rose to $104.9 million, and the company maintained its full year 2026 guidance.
MYQORZO net product revenue was $4.8 million, covering about 9 weeks of U.S. sales in the first quarter.
Revenue included an $11.9 million milestone tied to the first U.S. sale of MYQORZO under the Bayer license agreement.
SG&A expenses were $104.9 million versus $57.4 million a year earlier, mainly due to external costs of the MYQORZO commercial launch.
Cash, cash equivalents and investments were approximately $1.1 billion at March 31, 2026, down from $1.2 billion at December 31, 2025; full year 2026 combined GAAP R&D and SG&A guidance of $830 million to $870 million was maintained.
Cytokinetics reported fourth quarter and full year 2025 results and gave 2026 guidance, while its MYQORZO heart drug launches in the U.S. Revenue rose from a year earlier, but the net loss widened sharply as the company built out its commercial operations. The company's 2026 GAAP combined R&D and SG&A expense guidance of $830 million to $870 million signals continued heavy spending.
Q4 2025 total revenues were $17.8 million, up from $16.9 million in Q4 2024; full year 2025 revenues were $88.0 million, up from $18.5 million.
Q4 2025 net loss was $183.0 million, or $(1.50) per share, versus a $150.0 million loss, or $(1.26) per share, a year earlier; full year net loss was $785.0 million, or $(6.54) per share, versus $589.5 million, or $(5.26) per share, in 2024
Cash, cash equivalents and investments were approximately $1.22 billion at December 31, 2025, including $100 million from a Royalty Pharma loan tranche.
2026 GAAP combined R&D and SG&A expense guidance is $830 million to $870 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cytokinetics filing is on SEC EDGAR ↗. 8-K briefs of other companies →